PGNY vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

PGNY

31.7
AI Score
VS
CLOV Wins

CLOV

45.8
AI Score

Investment Advisor Scores

PGNY

32score
Recommendation
SELL

CLOV

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PGNY CLOV Winner
Revenue 1.02B 2.25B CLOV
Net Income 78.54M 61.77M PGNY
Net Margin 7.7% 2.7% PGNY
Operating Income 110.56M 61.77M PGNY
ROE 19.0% 15.8% PGNY
ROA 11.6% 8.2% PGNY
Total Assets 675.79M 753.68M CLOV
Current Ratio 1.93 1.55 PGNY
Free Cash Flow 131.05M 201.03M CLOV

Relative Price Performance (Last 90 Days)

PGNY 1M: +31.8% · 3M: +42.8% CLOV 1M: +6.0% · 3M: +16.2%

Current Technical Phase

PGNY

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.7% over 20 days), RSI 79

RSI (14): 79.3 · Price: $36.18

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 59

RSI (14): 58.5 · Price: $4.96

Fundamentals Snapshot

Metric PGNY CLOV
Market Cap — —
Forward P/E 15.1 27.6
Trailing P/E 33.6 488.0
Revenue (TTM) — —
Revenue Growth 0.1% 0.5%
Gross Margin 0.2% 0.2%
Operating Margin 0.1% 0.0%
EPS 1.09 0.01
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLOV is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.